Sunshine Biopharma, Inc. (SBFM) Announces Better-Than-Expected Results Of Pharmacokinetics Studies For Lead Anti-Cancer Compound

May 22, 2012 2:59 PM ETSBFM
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2008

QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit

Sunshine Biopharma announced today that it has completed the pharmacokinetics studies in live rats for its lead anti-tumor compound, Adva-27a. Pharmacokinetics studies deal with the determination of the fate of substances administered to a living organism; more specifically, pharmacokinetics studies deal with the study of the mechanisms of absorption and distribution of an administered drug and the rate at which a drug action begins and the duration of the effect.

Sunshine Biopharma's recently completed pharmacokinetics studies analyzed the properties of Adva-27a and Etoposide in the plasma of live rats under a single intravenous bolus injection. While both had a mean terminal phase plasma half-life of around one hour, Adva-27a produced a 2.8-fold higher plasma initial concentration (C0 = 8779 ng/mL) than Etoposide (C0 = 3183 ng/mL). Additionally, the area under the plasma concentration-versus-time curve for Adva-27a (AUCinf - 2211 hr-ng/mL) was 2.4-times higher than that of Etoposide (AUCinf = 933 hr-ng/mL). Adva-27a, moreover, had a significantly lower plasma clearance rate (CL = 19.0 mL/min/kg) compared to Etoposide (CL = 44.7 mL/min/kg).

The results indicate that Adva-27a's pharmacokinetics profile is significantly better than Etoposide's. This finding, coupled with Sunshine Biopharma's prior observation that Adva-27a can overcome multidrug resistance in breast cancer cells, further confirms the uniqueness of Adva-27a as an anti-cancer compound.

The company is presently conducting the next sequence of steps in its development of Adva-27a, which includes GMP manufacturing, IND-enabling studies, and filing an IND application, followed by phase I clinical trials in humans.

Sunshine Biopharma is a development-stage pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer.

For more information, visit the company's Web site at

Please see disclaimer on the QualityStocks website:

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.